anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Meperidine hydrochloride tablet is an opioid agonist, available as 50 mg and 100 mg tablets for oral administration. The chemical name is 4-Piperidinecarboxylic acid, 1-methyl-4-phenyl-,ethyl ester, hydrochloride. The molecular weight is 283.80. Its molecular formula is C15H21NO2•HCl, and it has the following chemical structure.

Meperidine hydrochloride is a white crystalline substance with a melting point of 186°C to 189°C. It is readily soluble in water and has a neutral reaction and a slightly bitter taste. The solution is not decomposed by a short period of boiling.

The tablets contain 50 mg or 100 mg of meperidine hydrochloride.

The inactive ingredients in meperidine hydrochloride tablets include: pregelatinized starch, microcrystalline cellulose, lactose monohydrate, silicon dioxide and stearic acid.
PCT No. PCT/GB93/01039 Sec. 371 Date Nov. 28, 1994 Sec. 102(e) Date Nov. 28, 1994 PCT Filed May 20, 1993 PCT Pub. No. WO93/23543 PCT Pub. Date Nov. 25, 1993The present invention provides novel peptides and vaccines containing them capable of inducing production of antibodies directed against Clostridium perfringens alpha-toxin (CPa) in animals to which they are administered and thereby providing prophylaxis against infection by Clostridium perfringens and/or the alpha-toxin itself. Particularly the present invention provides such a vaccine that is relatively safe and simple to produce. e.g. by genetic engineering means. Preferred peptides comprise theo amino acid sequence of Clostridium perfringens alpha-toxin from amino acid 247 to 370 but lack the epitopes necessary for phospholipase C and/or sphingomyelin hydrolysing activity found between amino acids 1 to 240 of that sequence. Further provided are antisera and antibodies raised to the peptides and vaccines of the present invention, and particularly monoclonal antibodies and hybridoma cell lines for their production.
Participants will receive nab-paclitaxel 125mg/m2; placebo IV; and then Gemcitabine 1000mg/m2, on Day 1, 8 and 15 of each cycle. Each cycle will be 28 days.
The use of large volumes of artificial priming fluids is still very high in cardiac surgery for routine CABG surgery with cardiopulmonary bypass. The resulting hemodilution is deleterious for patients and often requires counter measures to maintain fluid balance during and after surgery. Retrograde autologous priming and mannitol are simple low-cost solutions to the problem of hemodilution but their effectiveness, either alone or in combination, is unclear due to a lack of high-quality evidence. RAPPER-MAN is a single-centre 2x2 factorial cluster randomized trial. Participants will be randomly assigned (1:1:1:1 ratio) to the intervention groups: 1) Retrograde autologous priming (≥600 mL) + mannitol (0.3 g/kg bolus), 2) Retrograde autologous priming (≥600 mL) alone, 3) Conventional priming + mannitol (0.3 g/kg bolus), and 4) Conventional priming alone. The primary outcome is the change in hemoglobin concentration during cardiopulmonary bypass. Retrograde autologous priming will be performed within 10 minutes before, and mannitol will be added to the venous reservoir of the CPB machine within 5 minutes before, the start of cardiopulmonary bypass. The results of the larger trial are expected to have broad implications for fluid management in cardiac surgery in Canada.
PURPOSE: With the increasing aging of the population and the increasing incidence of chronic diseases in China, home hospice care services can meet the desire of the older adult with chronic diseases to receive care and die at home. In order to ensure the real application of hospice in families, the goal of the study was to construct a home hospice care program for the older adult at the end of life with chronic diseases based on Harmony Nursing Theory (composed of three parts: harmony needs assessment, harmony mechanism establishment and interpersonal interaction).
METHODS: Through literature review, a qualitative interview and group discussion, the first draft of a home hospice care program for the older adult at the end of life with chronic diseases based on the harmony nursing theory was developed, which was further revised and finalized by combining the Delphi method of expert correspondence with 19 experts and a pilot study with a home hospice care team.
RESULTS: A total of two rounds of expert correspondence were conducted. In the first round, 21 questionnaires were distributed and 19 were returned, yielding a recovery rate of 90.48%. In the second round, 19 questionnaires were distributed, and 19 questionnaires were collected. The recovery rate was 100%. The authority of the two rounds of expert correspondence was 0.96, and Kendall's coefficient of concordance (W) was 0.268 and 0.310, respectively. After the first round of Delphi expert consultation, 3 items were deleted, and 12 items were revised. In the second round of Delphi expert consultation, two items were revised. The final version of the home hospice program includes 4 first-level items, 20 second-level items, and 59 third-level items.
CONCLUSION: The home hospice care program based on harmony nursing theory is authoritative and scientific and can provide a reference for the practice of home hospice care for the older adult with chronic diseases.
The invention belongs to the technical field of medicines and relates to a novel application of ilex hainanensis merr total triterpenes. The invention discloses an application of ilex hainanensis merr total triterpenes to preparation of a weight-reducing and lipid-regulating pharmaceutical preparation, and provides the weight-reducing and lipid-regulating pharmaceutical preparation taking the ilex hainanensis merr total triterpenes as raw materials. The preparation comprises ilex hainanensis merr total triterpenes and at least one medicinal excipient. The ilex hainanensis merr total triterpenes have a very strong inhibiting effect on mouse obesity. An effective part can remarkably inhibit mouse obesity induced by a high-fat diet, and effectively reduce abdominal fat accumulation of mice. Likewise, the effective part can remarkably lower TC (total cholesterol), TG (triglyceride) and LDL-C (low-density lipoprotein cholesterol) levels of the obese mice. Therefore, the ilex hainanensis merr total triterpenes have the effects of reducing weight and regulating blood lipid. The ilex hainanensis merr total triterpenes can be used for preparing weight-reducing and lipid-regulating medicines and drugs for preventing obesity or health foods.
Photosensitive texaphyrins may be used for photodynamic therapy of conditions of the eye characterized by abnormal vasculature, such as macular degeneration, glaucoma, myopia or pterygium.   The photosensitive texaphyrin may be a free-base texaphyrin or preferably metallated with a diamagnetic cation, such as lutetium. Detectable texaphyrins may be used as contrast agents for carrying out ocular angiography.  When the detectable texaphyrin is fluorescent, the vasculature state of the eye may be observed by fluorescence.  Alternatively, the texaphyrin may be complexed with a paramagnetic cation and observed by magnetic resonance imaging. Due to the dual wavelength absorption of texaphyrins at 400-500 nm and at 700-800 nm, texaphyrins are more effective and versatile for use in humans as compared to porphyrins.
Phase I Part A will evaluate the safety and pharmacokinetics (PK)of a range of OP-1250 doses to identify the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D). Phase I Part B will evaluate the safety and PK of OP-1250 to confirm the RP2D dose.
A method and a device for separating a component, such as fibrin I from blood, by centrifugation. The method involves feeding of blood admixed an anticlotter to a first annular chamber in a device, where the annular chamber is defined by a cylindrical outer wall and a cylindrical inner wall, both walls extending coaxially about a common axis, as well as by a top wall and a bottom wall, where the top wall or the bottom wall is formed by a piston body displaceable within the first chamber. The method involves furthermore a centrifugation of the device about the said common axis followed by a resulting liquid fraction being transferred while influenced by the piston body to a second chamber defined by an outer cylindrical wall, which extends coaxially with said common axis. As a result the liquid fraction present in the second chamber is caused to be further separated by a continued centrifugation and addition of suitable compositions promoting the separation and returning of the non-utilizable portion to the first chamber. In addition, the portion of the liquid fraction remaining in the second chamber is transferred to a liquid-receiving container through a filter optionally after addition of a solvent. The portion of the liquid fraction remaining in the second chamber prior to the transfer to the liquid-receiving container is transferred to a third chamber coaxially accommodated with the other chambers, and the liquid now present in said third chamber is caused to pass through an annular filter during the centrifugation so as to enter an annular outer compartment which is adapted to be connected to the liquid-receiving member.
FIELD: organic chemistry, pharmacy. SUBSTANCE: invention relates to novel oxazolidinone derivatives of the formula (I)  , their enantiomers or their pharmaceutically acceptable salts wherein R means hydrogen atom or C 1-6 -alkyl optionally substituted with group taken among cyano-, fluorine, chlorine atom, hydroxy- or carbamoyl; R 1  and R 2  represent independently fluorine or hydrogen atom; R 3  represents C 1-6 -alkyl; X represents oxygen or sulfur atom. Invention relates to pharmaceutical compositions eliciting an antibacterial effect and containing compound of the formula (I) as an active component and pharmaceutically acceptable carrier. Invention provides preparing the novel compound eliciting an antibacterial effect. EFFECT: valuable medicinal property of derivatives. 8 cl, 1 tbl, 5 ex
There are clinical situations where information about the anticoagulant effects of Apixaban could be useful. Specialised methods for measuring Apixaban concentrations are not available at all medical laboratories while methods for measuring the functional effects of Apixaban, using clot time ratio (CTR), can be performed in most medical laboratories around the clock using well-established measurement procedures. The aim of this study was to investigate CTR in trough and peak samples during Apixaban treatment of atrial fibrillation and to correlate the findings to bleeds and thrombotic events. Three trough- and three peak samples from 61 patients (31 on Apixaban 5 mg twice daily and 30 on Apixaban 2.5 mg twice daily) were analysed with MRX PT DOAC. Patients were followed for 30 + /-15 months, and bleeds and thrombotic events were documented. The effect of Apixaban could be measured with MRX PT DOAC and there was a statistically significant difference between CTR in trough samples compared to peak samples (p < 0.001). A total of 21 patients suffered bleeds during follow-up; two patients suffered major bleeds, and 19 suffered minor bleeds. Patients with major bleeds had both mean peak- and mean trough CTR above the respective first to third quartile (Q1-Q3) range. Four patients suffered thromboembolic events. Generally, the peak CTRs were below or in the lower end of the peak Q1-Q3 for these patients. The new test MRX PT DOAC can be used to measure the effect of Apixaban during the treatment of atrial fibrillation. High mean peak- and mean trough CTR were seen in 2 patients with major bleeds, and low peak CTR was seen in 4 patients with thromboembolic events.
Novel and useful compositions derived from rooibos for treating diabetes are provided. The present invention is particularly concerned with the treatment of Type 2 diabetes. The invention provides a new use for aspalathin and rutin and compositions containing them for use in the prevention and treatment of diabetes. The invention provides an anti-diabetic agent, an anti-diabetic composition containing the anti-diabetic agent, a foodstuff or beverage containing the anti-diabetic agent, a method for preventing or treating diabetes or impaired glucose tolerance, and a method of decreasing blood glucose level. The anti-diabetic agent may be an extract from rooibos ( Aspalathus  spp.), aspalathin as such or in combination with rutin.
Leukotrienes plays an important role as mediator for inflammatory changes in acute as well as chronic asthma. There are three randomized controlled trials involving 274 adult patients with acute asthma who were treated with montelukast (intravenous in 2 and intravenous and oral in one study) to see the beneficial response in spirometry. All the studies showed significant improvement in FEV1 in first 2 hours. These studies show that oral montelukast causes improved pulmonary function and has a rapid onset of action. However, these studies are carried out in adults. Safety of oral montelukast is well established in children, as evidenced by use of oral montelukast in long term management of asthma.

Therefore, we planned this study to see the effect of oral montelukast as add on therapy to standard treatment in acute moderate to severe asthma in children between 5-15 years of age.
<P>PROBLEM TO BE SOLVED: To obtain an aldose reductase inhibitor for preventing or treating nervous disorders complicated by diabetes, and the like.  <P>SOLUTION: The stems and branches of a tree are crushed and then extracted with water or ethanol. Thus, the aldose reductase inhibitor having high safety for human bodies can simply be obtained. The tree is preferably a tree from which an extract giving a final extract concentration of ≤10 ppm at an aldose reductase inhibition rate of 50 % can be extracted. When the aldose reductase inhibitor is extracted, water, an organic solvent such as a lower alcohol or ethyl acetate, or the like, can be used as an extracting liquid.  <P>COPYRIGHT: (C)2006,JPO&NCIPI
The deleterious effects of mental fatigue (MF) on athletes have been carefully studied in various sports, such as soccer, badminton, and swimming. Even though many researchers have sought ways to ameliorate the negative impact of MF, there is still a lack of studies that review the interventions used to counteract MF among athletes. This review aims to report the current evidence exploring the effects of interventions on MF and sport-specific performance, including sport-specific motor performance and perceptual-cognitive skills. Web of Science, Scopus, PubMed, and SPORTDicus (EBSCOhost) were combed through to find relevant publications. Additionally, the references and Google Scholar were searched for any grey literature. For the current review, we included only randomized controlled trials that involved athletes, a primary task to induce MF, interventions to counter MF with comparable protocols, and the outcomes of sport-specific motor performance and perceptual-cognitive skill. The selection criteria resulted in the inclusion of 10 articles. The manipulations of autonomous self-control exertion, person-fit, nature exposure, mindfulness, and transactional direct current stimulation showed that positive interventions counteract MF and improve sport-specific performance in different domains, including strength, speed, skill, stamina, and perceptual-cognitive skills. The selected interventions could significantly counteract MF and improve subsequent sport-specific performance. Moreover, self-regulation and attention resources showed the importance of the potential mechanisms behind the relevant interventions.
The invention relates to a chalcone compound with an oxyacetic acid structure. The chalcone compound is artificially synthesized 4-nitro-2' -carboxymethoxy chalcone. The new compound synthesized by the invention has a structure similar to a natural product, the raw materials are cheap and easy to obtain, the reaction condition is mild, and the operation is simple. TLC chart and melting point determination show that the obtained compound has higher purity, and the IR and MS spectrums thereof are consistent with the structure of the target product. Experiments show that the compound has certain activity of resisting escherichia coli, staphylococcus aureus and salmonella, and has stronger bacteriostatic effect on the escherichia coli and the salmonella compared with the control penicillin sodium. The invention also provides application of the chalcone compound with the oxyacetic acid structure, in particular to application of the chalcone compound in preparing antibacterial drugs. The invention also provides an antibacterial agent, and the active component of the antibacterial agent is the chalcone compound with the oxyacetic acid structure.
The invention belongs to the field of biomedicine, and particularly relates to an aluminum hydroxide gel-polysaccharide composite immunologic adjuvant and a preparation method and application thereof. The invention aims to provide a new immunologic adjuvant with good performance. The technical scheme is to provide a composite immunologic adjuvant. The composite immunologic adjuvant mainly contains aluminum hydroxide gel and polysaccharide serving as bacteria source. The aluminum hydroxide gel-polysaccharide composite immunologic adjuvant provided by the invention has the advantages of strong immunocompetence, high clinical safety and the like, and is an excellent composite immunologic adjuvant aiming at various antigens. The hepatitis vaccine and tumor vaccine prepared by taking the aluminum hydroxide gel-polysaccharide composite provided by the invention as adjuvant has stronger immune effect and anti-cancer effect, and thus new selection is provided for the development and application of vaccine.
Provided is a novel method for detecting Transmissible Spongiform encephalopathies (TSE). The method comprises: selecting a sera sample from a subject to determine whether the subject has transmissible spongiform encephalopathy; and detecting antibodies that immune react with  Spiroplasma  proteins in the sample. The method detects antibodies in the individual sera samples that react with recombinant  Spiroplasma -specific Hsp60 by standard ELISA methodology. This method provides for rapid detection of TSE by determination of presence of antibodies in test sera showing associated  Spiroplasma  infection that has become consistent with presence of TSE. The method provides a mechanism to detect presence of TSE without invasive techniques currently needed to make diagnosis using brain tissues for prion detection. This method provides means of detection of TSE in the live patient without need for using necropsy tissues. This method provides the first method discovered that detects antibodies against TSE infection-specific proteins in sera or cerebrospinal fluid samples.
BACKGROUND: Revision of radial head arthroplasty (RHA) may be indicated in cases of prosthesis loosening and malposition. Inherent difficulties in revision surgery include poor bone stock and disrupted soft tissue envelope. Although cases of RHA used for revision of failed RHA are rare, there is reasonable expectation for increasing frequency of these cases due to the increasing incidence of primary RHA. Furthermore, there is an increasing demand for postoperative recovery of function; thus, surgeons may consider revising a failed RHA to a new RHA. We report on series of failed RHA which were revised to a new radial head prosthesis.
METHODS: A retrospective review was performed at multiple institutions for a single radial head prosthesis used for revision of a failed radial head prosthesis. Clinical and radiographic outcomes were collected with a minimum of 1 year of follow-up.
RESULTS: Across 11 patients at a mean follow-up of 45.1 months, the mean Mayo Elbow Performance Score was 81.7; mean Disabilities of the Arm, Shoulder, and Hand scores were 24.4; and mean Visual Analog Scale for pain was 0.6. Radiographic analysis yielded no evidence of capitellar wear or stem loosening.
CONCLUSION: A radial head prosthesis can produce satisfactory results when used for revision of a failed prosthesis. Inherent difficulties in revision surgery include the potential for reduced bone stock and a disrupted soft tissue envelope. Elements of prosthesis design which may contribute to effectively managing revision surgery include a long stem with in-growth surface and prosthetic head alignment to the axis of forearm rotation.
BACKGROUND AND AIMS: The natural history of untreated patients with type 1 Gaucher disease (GD1) is not well documented, and there is controversy over when and how to treat such patients, especially if they are only mildly symptomatic. Treatment of GD1 is inconvenient, very costly, and may result in undesirable side effects. We documented the clinical history of 31 untreated patients with GD1 followed in our clinic for 4-26 (median 15) years.
METHODS: This was a retrospective, observational study of the progress of untreated adult patients with GD1 followed by blood tests (haemoglobin, platelet counts, ferritin and chitotriosidase), organ volumes (spleen and liver), bone manifestations (through magnetic resonance imaging and dual X-ray absorptiometry scans) and neurological and quality of life issues. Statistical analyses were performed with the use of the Student paired t test and the modified Wald test for 95% confidence intervals.
RESULTS: We found that the above parameters remained stable in most patients over a period of 4-26 (median 15) years. Five patients progressed from normal bone density to osteopenia and two from osteopenia to osteofibrosis; six were peri- or post-menopausal females. The DS-3 was stable over time. Only four of the 31 patients were started on enzyme or substrate reduction therapy.
CONCLUSIONS: Our results demonstrate that many patients with GD1, provided with close follow-up by a specialist centre, can be followed for many years without requiring treatment and with no or minimal worsening of their GD1 manifestations.
To provide an anti-photo aging agent with a novel component as an effective component.SOLUTION: Features of the present invention for solving the above problems are as follows. 1. A cell atrophy inhibitor due to UVA irradiation on fibroblast cells with a Psoralea extraction as an effective component. 2. A cell atrophy inhibitor due to UVA irradiation in a fibroblast cells with bakuchiol as an effective component. 3. A collagen gel shrinkability increasing agent with the Psoralea extraction as an effective component. 4. A collagen gel shrinkability increasing agent with bakuchiol as an effective component. 5. An integrin α1 increasing agent with the Psoralea extraction as an effective component. 6. An integrin α1 increasing agent with bakuchiol as an effective component. 7. an anti-photo aging agent with a preparation described in any one of 1. to 6.SELECTED DRAWING: None
Seborrheic keratosis(SK) is a very common skin tumor which is mostly frequently observed in the trunck, head, neck. SK in the auricle is rare and this condition should be excluded the possibility of malignancy by pathologic diagnosis. We report a case of 66-year-old man who presented with a brownish, papillomatous, verrucous mass in the auricle for the past seven years, which began to growing faster during the previous year. Dermoscopy and histopathological examination were performed and the patient was diagnosed with SK. He was treated with the carbon dioxide(CO2) laser and aminolevulinate photodynamic therapy (ALA-PDT). The CO2 laser was used for the removal of the thick hypertrophic lesions and to enhance the transdermal absorption efficiency of ALA. A 20% ALA cream(118 mg/cm2) was applied to his lesion and sealed for 3 h without light, followed by irradiation with 630-nm LED light (96 J/cm2, 80 mw/cm2). We use fluorescent diagnosis with aminolevulinic acid to define the tumor margins at the first session of ALA-PDT. After 4 sessions of ALA-PDT, the lesion was completely removed and did not recur. Therefore, we consider that ALA-PDT combined with CO2 laser is a safe and effective choice for the treatment of seborrheic keratosis in the auricle.